<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01223378</url>
  </required_header>
  <id_info>
    <org_study_id>659</org_study_id>
    <nct_id>NCT01223378</nct_id>
  </id_info>
  <brief_title>Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Randomized, Multicenter, Single-Masked, Parallel-Group Dose Finding Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Open Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical investigation is to determine the most effective drug
      concentration(s) of BOL-303259-X in the reduction of IOP in order to support further clinical
      development of an appropriate dose with regard to efficacy, and ocular and systemic safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of Mean Diurnal IOP</measure>
    <time_frame>Day 28</time_frame>
    <description>Determine the most effective drug concentration(s) of BOL-303259-X in the reduction of intraocular pressure (IOP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of mean diurnal IOP</measure>
    <time_frame>Over all study visits through day 28</time_frame>
    <description>Determine the concentration of BOL-303259-X that is superior to the latanoprost ophthalmic solution in the mean reduction of diurnal IOP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP &lt;/=18mm Hg</measure>
    <time_frame>Over all study visits through day 28</time_frame>
    <description>Determine the number of subjects with IOP &lt;/=18 with BOL-303259-X versus latanoprost ophthalmic solution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular and systemic adverse events</measure>
    <time_frame>Over all study visits through day 28</time_frame>
    <description>BOL-303259-X versus latanoprost ophthalmic solution with regard to ocular and systemic adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">355</enrollment>
  <condition>Intraocular Pressure</condition>
  <arm_group>
    <arm_group_label>BOL-303259-X</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latanoprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ophthalmic solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: BOL-303259-X</intervention_name>
    <description>ophthalmic solution, various concentrations, once daily (QD) 28 days</description>
    <arm_group_label>BOL-303259-X</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost</intervention_name>
    <description>0.005% ophthalmic solution, QD 28 days</description>
    <arm_group_label>Latanoprost</arm_group_label>
    <other_name>Xalatan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have a diagnosis of open angle glaucoma (OAG) or ocular hypertension
             (OH) in one or both eyes.

        Exclusion Criteria:

          -  Subjects with a known hypersensitivity or contraindications to latanoprost or any of
             the ingredients in the study drugs.

          -  Subjects with closed or barely open anterior chamber angle or a history of acute angle
             closure in either eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rabia Ozden, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb, Inc</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2010</study_first_submitted>
  <study_first_submitted_qc>October 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2010</study_first_posted>
  <disposition_first_submitted>August 10, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>August 10, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 20, 2012</disposition_first_posted>
  <last_update_submitted>November 22, 2013</last_update_submitted>
  <last_update_submitted_qc>November 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 18, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

